CTLA4 and heart failure: It is reported that an incidence of up to 19% in all patients receiving immunotherapy, who received anticancer therapy, included an anthracycline, cyclophosphamide, trastuzumab, and anti-CTLA4 or anti-PD-1/PD-L1, with an incidence of cardiac insufficiency (with the New York Heart Association (NYHA)III or IV).